Evofem Biosciences, Inc. (EVFM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 7M 14M 21M Q2 '20: 0 Q3 '20: 278K Q4 '20: 446K Q1 '21: 1.6M Q2 '21: 3.4M Q3 '21: 4.8M Q4 '21: 8.2M Q1 '22: 11.4M Q2 '22: 15.6M Q3 '22: 20.2M Q4 '22: 16.8M Q1 '23: 18.4M Q2 '23: 14.8M Q3 '23: 13.6M Q4 '23: 18.2M Q1 '24: 16M Q2 '24: 17.7M Q3 '24: 17.1M Q4 '24: 19.4M Q1 '25: 16.6M Q2 '25: 17.3M Q3 '25: 17.7M Q4 '25: 20.2M Q1 '26: 20.2M Q2 '26: 18M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

-6M 0 6M 12M 18M Q2 '20: 0 Q3 '20: -39K Q4 '20: -22K Q1 '21: 577K Q2 '21: 1.6M Q3 '21: 2.4M Q4 '21: 4.2M Q1 '22: 6.8M Q2 '22: 10.5M Q3 '22: 14.4M Q4 '22: 12.4M Q1 '23: 13.7M Q2 '23: 9.1M Q3 '23: 7.6M Q4 '23: 11.7M Q1 '24: 10.2M Q2 '24: 13.4M Q3 '24: 13.8M Q4 '24: 15.5M Q1 '25: 13.1M Q2 '25: 13.8M Q3 '25: 14.2M Q4 '25: 15.6M Q1 '26: 15.6M Q2 '26: 13.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '14: -9.6M Q1 '15: -13.7M Q2 '15: -21M Q3 '15: -36.1M Q4 '15: -42M Q1 '16: -41.2M Q2 '16: -34.5M Q3 '16: -19.4M Q4 '16: -12.2M Q1 '17: -11.3M Q2 '17: -15.1M Q3 '17: -22.3M Q4 '17: -35.7M Q1 '18: -51.8M Q2 '18: -68.6M Q3 '18: -78M Q4 '18: -77.6M Q1 '19: -70.3M Q2 '19: -59M Q3 '19: -54.9M Q4 '19: -52.7M Q1 '20: -58.4M Q2 '20: -68.8M Q3 '20: -80.6M Q4 '20: -103.6M Q1 '21: -129.3M Q2 '21: -148M Q3 '21: -165.2M Q4 '21: -166.8M Q1 '22: -150.9M Q2 '22: -134.1M Q3 '22: -109.5M Q4 '22: -84.1M Q1 '23: -58.8M Q2 '23: -41.7M Q3 '23: -26.5M Q4 '23: -17.8M Q1 '24: -17.1M Q2 '24: -11.2M Q3 '24: -10.1M Q4 '24: -7.7M Q1 '25: -4.5M Q2 '25: -4.4M Q3 '25: -976K Q4 '25: 3.4M Q1 '26: -1.5M Q2 '26: -2.8M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q4 '14: -10.8M Q1 '15: -16.1M Q2 '15: -23.3M Q3 '15: -36.5M Q4 '15: -43.2M Q1 '16: -42.3M Q2 '16: -35.5M Q3 '16: -20.6M Q4 '16: -25.3M Q1 '17: -24.5M Q2 '17: -28.4M Q3 '17: -100M Q4 '17: -105.3M Q1 '18: -169.1M Q2 '18: -185.8M Q3 '18: -130.2M Q4 '18: -125.7M Q1 '19: -74.7M Q2 '19: -86.9M Q3 '19: -82.3M Q4 '19: -80M Q1 '20: -81.1M Q2 '20: -98.3M Q3 '20: -114.4M Q4 '20: -142.3M Q1 '21: -169.3M Q2 '21: -150.1M Q3 '21: -194.2M Q4 '21: -205.2M Q1 '22: -190.9M Q2 '22: -283.5M Q3 '22: -119.9M Q4 '22: -76.7M Q1 '23: -47.2M Q2 '23: 70.3M Q3 '23: 46.8M Q4 '23: 53M Q1 '24: 50.5M Q2 '24: 60.4M Q3 '24: -7.9M Q4 '24: -8.9M Q1 '25: -3.1M Q2 '25: -6.2M Q3 '25: -5.4M Q4 '25: 391K Q1 '26: -6M Q2 '26: -15.3M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue TTM

0 2.5M 5M 7.5M Q2 '20: 0 Q3 '20: 317K Q4 '20: 468K Q1 '21: 974K Q2 '21: 1.8M Q3 '21: 2.5M Q4 '21: 4.1M Q1 '22: 4.6M Q2 '22: 5.1M Q3 '22: 5.8M Q4 '22: 4.4M Q1 '23: 4.7M Q2 '23: 5.7M Q3 '23: 5.9M Q4 '23: 6.5M Q1 '24: 5.8M Q2 '24: 4.3M Q3 '24: 3.3M Q4 '24: 3.8M Q1 '25: 3.5M Q2 '25: 3.5M Q3 '25: 3.5M Q4 '25: 4.6M Q1 '26: 4.7M Q2 '26: 4.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '14: -9.6M Q1 '15: -11.6M Q2 '15: -17.5M Q3 '15: -27.5M Q4 '15: -37.9M Q1 '16: -40.7M Q2 '16: -35.5M Q3 '16: -26.9M Q4 '16: -16.3M Q1 '17: -14.7M Q2 '17: -15.6M Q3 '17: -8.7M Q4 '17: -19.2M Q1 '18: -31.3M Q2 '18: -47M Q3 '18: -59.7M Q4 '18: -56.5M Q1 '19: -46M Q2 '19: -46.4M Q3 '19: -51.9M Q4 '19: -55.1M Q1 '20: -62.3M Q2 '20: -57.8M Q3 '20: -79.2M Q4 '20: -104.8M Q1 '21: -124.4M Q2 '21: -162.9M Q3 '21: -164.5M Q4 '21: -146.7M Q1 '22: -133.1M Q2 '22: -106.2M Q3 '22: -85.1M Q4 '22: -70.4M Q1 '23: -54.4M Q2 '23: -29.3M Q3 '23: -15.3M Q4 '23: -9M Q1 '24: -3.9M Q2 '24: -3.6M Q3 '24: -1.6M Q4 '24: -3.9M Q1 '25: -3.4M Q2 '25: -5.2M Q3 '25: -4.4M Q4 '25: -2M Q1 '26: -251K Q2 '26: -472K Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '14: -9.6M Q1 '15: -11.8M Q2 '15: -17.7M Q3 '15: -27.7M Q4 '15: -38.1M Q3 '20: -80.2M Q4 '20: -107.1M Q1 '21: -127.5M Q2 '21: -166.9M Q3 '21: -168.8M Q4 '21: -149.6M Q1 '22: -135.2M Q2 '22: -107.1M Q3 '22: -85.5M Q4 '22: -70.8M Q1 '23: -54.7M Q2 '23: -29.4M Q3 '23: -15.4M Q4 '23: -9M Q1 '24: -3.9M Q2 '24: -3.6M Q3 '24: -1.7M Q4 '24: -3.9M Q2 '26: -477K Q2 '15 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 2.5B 5B 7.5B Q2 '20: 57.7M Q3 '20: 81.2M Q1 '21: 5.5M Q2 '21: 8.3M Q3 '21: 10.3M Q1 '22: 11.1M Q2 '22: 217K Q3 '22: 4.4M Q1 '23: 1.3M Q2 '23: 1.6M Q3 '23: 730M Q1 '24: 31.2M Q2 '24: 1.6B Q3 '24: 96.5M Q1 '25: 6.2B Q2 '25: 120.5M Q3 '25: 119.6M Q1 '26: 133.2M Q2 '26: 137.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-750.00 -500.00 -250.00 0.00 250.00 500.00 750.00 Q4 '14: -5.36 Q1 '15: -2.86 Q2 '15: 0.58 Q3 '15: 6.63 Q4 '15: -18.90 Q1 '16: -18.84 Q2 '16: -18.34 Q3 '16: -17.25 Q4 '16: -0.99 Q1 '17: -3.69 Q2 '17: -7.28 Q3 '17: -45.42 Q4 '17: -55.78 Q1 '18: -57.26 Q2 '18: -54.59 Q3 '18: -16.99 Q4 '18: -7.02 Q1 '19: -3.07 Q2 '19: -2.93 Q3 '19: -2.52 Q4 '19: -2.21 Q1 '20: -1.94 Q2 '20: -1.88 Q3 '20: -1.95 Q4 '20: -2.17 Q1 '21: -10.23 Q2 '21: -13.33 Q3 '21: -20.16 Q4 '21: -24.21 Q1 '22: -18.63 Q2 '22: -595.10 Q4 '23: 0.05 Q1 '24: 1.74 Q2 '24: 7.17 Q3 '24: 7.05 Q4 '24: -0.11 Q1 '25: 0.05 Q2 '25: 0.04 Q3 '25: 0.05 Q4 '25: 0.00 Q1 '26: -0.04 Q2 '26: -0.11 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.